Zobrazeno 1 - 10
of 669
pro vyhledávání: '"XELOX"'
Autor:
Taishi Hata, Mamoru Uemura, Katsuki Danno, Shinichi Yoshioka, Chu Matsuda, Yoshinori Kagawa, Tatsushi Shingai, Yozo Suzuki, Mitsuyoshi Tei, Tsukasa Tanida, Takamichi Komori, Shu Okamura, Hirofumi Ota, Hiroyoshi Takemoto, Takayuki Ogino, Norikatsu Miyoshi, Hirofumi Yamamoto, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Adjuvant oxaliplatin plus capecitabine (XELOX) therapy is recommended for patients with curatively resected colon cancer. However, prospective data on its practical application in Japanese patients are limited. Therefore, we aimed to conduct
Externí odkaz:
https://doaj.org/article/8397edc0e89c4d1c838969c4c7173351
Autor:
Zhen-Hao Li, Ting Xu, Ya-Juan Zhang, Jing-Hang Jiang, Yu-Ze Mi, Jia-Xuan Li, Jing Shen, Yi-Rui Fu, Bo-Ying Qin, Fan Lin, Dong-Jing Fu, Mei-Jin Yue, Shu-Mei Ma, Quan-Fu Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectivesIn this study, we compared the dynamic changes in body composition during XELOX/SOX chemotherapy in patients with gastric cancer. Furthermore, we investigated the potential impact of these changes on the occurrence of toxic side effects.Met
Externí odkaz:
https://doaj.org/article/1a5221a297204507a40b27e3bde625ed
Publikováno v:
Arabian Journal of Chemistry, Vol 17, Iss 3, Pp 105625- (2024)
Ulcerative colitis (UC) is an autoimmune disease with a steady increase in global prevalence and long-term susceptibility to colorectal cancer (CRC). CRC is often treated with XELOX regimen (oxaliplatin and capecitabine), which is limited by the high
Externí odkaz:
https://doaj.org/article/c075ba1171394a90a057067e109f4e73
Autor:
Yizhang Chen, Jiaguang Zhang, Gaohua Han, Jie Tang, Fen Guo, Wei Li, Li Xie, Hao Xu, Xinyi Zhang, Yitong Tian, Lanlan Pan, Yongqian Shu, Ling Ma, Xiaofeng Chen
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe efficacy of current adjuvant chemotherapy for gastric adenocarcinoma/gastroesophageal junction adenocarcinoma (GA/GEJA) leaves much to be desired. ctDNA could serve as a potential marker to identify patients who are at higher risk of re
Externí odkaz:
https://doaj.org/article/c8bf16b915c24202b03fb8be5c0efd03
Autor:
Bo Song, Hai Hu, Li Zhang, Su-Juan Ye, Yong-Dong Jin, Chang-Ling Shang, Jun Zhang, Hao Sun, Ke Zhang, Bo Yi, Yun-Wei Han, Jin Yan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAnlotinib showed encouraging anti-tumor activity in metastatic colorectal cancer (mCRC). This study was designed to assess the efficacy and safety of anlotinib plus XELOX as first-line therapy in mCRC patients.Materials and MethodsEligible
Externí odkaz:
https://doaj.org/article/dba4766f295649ba9bb97e7b89b04b45
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiao‐Dong Zhu, Ming‐Zhu Huang, Yu‐Sheng Wang, Wan‐Jing Feng, Zhi‐Yu Chen, Yi‐Fu He, Xiao‐Wei Zhang, Xin Liu, Chen‐Chen Wang, Wen Zhang, Jie‐Er Ying, Jun Wu, Lei Yang, Yan‐Ru Qin, Jian‐Feng Luo, Xiao‐Ying Zhao, Wen‐Hua Li, Zhe Zhang, Li‐Xin Qiu, Qi‐Rong Geng, Jian‐Ling Zou, Jie‐Yun Zhang, Hong Zheng, Xue‐Feng Song, Shu‐Sheng Wu, Cheng‐Yan Zhang, Zhe Gong, Qin‐Qin Liu, Xiao‐Feng Wang, Qi Xu, Qi Wang, Jian‐Mei Ji, Jian Zhao, Wei‐Jian Guo
Publikováno v:
Cancer Communications, Vol 42, Iss 4, Pp 314-326 (2022)
Abstract Background There is no consensus on whether triplet regimen is better than doublet regimen in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine (XELOX) a
Externí odkaz:
https://doaj.org/article/3847a66d6c7b4f0a892d3bcfe99399f3
Autor:
Temraz S, Nasr F, Kattan J, Abigerges D, Moukadem W, Farhat F, Maatouk L, Chahine G, Shamseddine A
Publikováno v:
Biologics: Targets & Therapy, Vol Volume 16, Pp 7-15 (2022)
Sally Temraz,1 Fadi Nasr,2 Joseph Kattan,3 Dany Abigerges,4 Walid Moukadem,5 Fadi Farhat,6 Layal Maatouk,7 Georges Chahine,8 Ali Shamseddine1 1Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; 2Department
Externí odkaz:
https://doaj.org/article/f8a0a262fec5418e84e36f934e1f9862
Autor:
Kyaw Z. Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Siqing Fu, Vivek Subbiah, David S. Hong, Timothy A. Yap, Jatin Shah, Denái R. Milton, Lacey McQuinn, Jing Gong, Yanyan Tran, Brett W. Carter, Rivka Colen, Funda Meric-Bernstam, Aung Naing
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-6 (2021)
Abstract Selinexor, an oral selective inhibitor of nuclear export (SINE), was demonstrated to hinder the DNA damage repair (DDR) system by reducing DDR proteins while enhancing the killing of cancer cells by DDR-based therapeutics in vivo studies. In
Externí odkaz:
https://doaj.org/article/c459d13c2a2d4dd98828b2e651417c38
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: The aim of the present Bayesian network meta-analysis (NMA) was to explore the comparative effectiveness and safeaty of different Chinese Medicine injections (CMIs) combined with the XELOX regimen versus XELOX alone for colorectal cancer (
Externí odkaz:
https://doaj.org/article/4eaf1825e79b42a2a2ad16588faefec0